How Analysts Feel About Casi Pharmaceuticals Incorporated (NASDAQ:CASI) After Increase in Sellers?

January 14, 2018 - By Darrin Black

 How Analysts Feel About Casi Pharmaceuticals Incorporated (NASDAQ:CASI) After Increase in Sellers?

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It worsened, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.
Guggenheim Cap holds 12,242 shares or 0% of its portfolio. Jpmorgan Chase And holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 9 shares. Howland Capital Management Ltd Liability Company holds 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) or 24,139 shares. Moreover, Moors & Cabot has 0.01% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 26,053 shares. 15,090 are owned by Manatuck Hill Partners Limited Liability Corp. Renaissance Tech Ltd Liability, New York-based fund reported 112,900 shares. Royal Fincl Bank Of Canada reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wells Fargo And Commerce Mn invested in 68 shares or 0% of the stock. California Employees Retirement Systems reported 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). The New York-based Wellington Shields Cap Management Limited Liability has invested 0.17% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). The New York-based Blackrock Inc has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris And Communication Ca holds 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) or 10,002 shares. 31,034 were reported by Northern Trust Corp. State Bank Of America De has invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Vanguard Group holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 358,972 shares.

The stock of Casi Pharmaceuticals Incorporated (NASDAQ:CASI) registered an increase of 19.72% in short interest. CASI’s total short interest was 745,400 shares in January as published by FINRA. Its up 19.72% from 622,600 shares, reported previously. With 458,200 shares average volume, it will take short sellers 2 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Incorporated’s float is 2.06%.

The stock decreased 0.79% or $0.03 during the last trading session, reaching $3.75. About 281,022 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since January 14, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $244.00 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. Maxim Group initiated the shares of CASI in report on Thursday, September 22 with “Buy” rating. On Monday, August 14 the stock rating was maintained by Maxim Group with “Buy”. The firm has “Buy” rating given on Thursday, October 29 by H.C. Wainwright.

More news for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) were recently published by: Prnewswire.com, which released: “CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer” on May 18, 2017. Prnewswire.com‘s article titled: “CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study …” and published on April 14, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.